Medical Weight Loss

TIRZEPATIDE

·       Dual GLP-1 and GIP receptor agonist that target incretin hormones that signal the pancreas and other organs to regulate blood sugar appetite and digestion. Has shown to produce greater weight loss than GLP-1 alone.

·       GLP-1: Glucagon like peptide

·       GIP: Glucose dependent insulinotropic polypeptide

EFFECTS

·       Reduced appetite: targets brain receptors in the hypothalamus to reduce hunger

·       Delayed gastric emptying: Keeping you feeling full longer after meals

·       Managing blood sugar: It stimulates insulin production from the pancreas only when glucose levels are high

·       Glucagon Suppression: Binds to GLP-1 receptors in the pancreas which suppresses the release of glucagon

·       Energy Expenditure and lipid metabolism: Tirzepatide has been shown to increase expenditure and promote fat burning reducing body weight. Has a positive impact on lipid metabolism improving cholesterol and triglyceride levels

·       Cardiac: Improves cardiovascular outcome in people with diabetes. Reduced cardiovascular death and heart failure events. Improved exercise capacity in patients with Heart Failure (HFpEF)

·       Reduced inflammation:

·       Decreases Liver Fat: Improve metabolic function in patients with steatotic liver disease. Reduced liver fibrosis

SIDE EFFECTS

·       Common: nausea, vomiting, constipation, diarrhea, injections site reactions

·       Uncommon: Pancreatitis, gallstones, kidney problems, allergic reactions

·       Contraindications: A personal or family history of medullary thyroid cancer or multiple endocrine neoplasia. Animal studies have linked these drugs with thyroid tumors. Breastfeeding or pregnant

Dosing

·       Inject 2.5mg SubQ once weekly. Titrate only as directed.

Studies

·       SURPASS 1-6; CVOT. SURMOUNT 1-4; OSA. SUMMIT, SYNERGY-NASH